Skip to main content

Replies sorted oldest to newest

Hi Kerry,

I'm not sure who your audience is for your project on economic costs, but I find it's helpful to bring out "the big guns" - peer-reviewed research publications because of their stringent approval process.  

I thought it may help to know that the medical community has also been looking at the "costs of ACES" and there is an article in the Oct 1st, 2019 issue of The Lancet.  The authors did a meta-analysis and systemic analysis of the life costs for individuals with ACES.  This is related to your search for economic costs in that this article goes deep into medical costs associated with individuals with ACES.  I thought this might be useful to support your work since The World Health Organization has funded and published this research for the medical community.  

In the summary of this report, is the gem statement "Total annual costs attributable to ACEs were estimated to be US$581 billion in Europe and $748 billion in north America. More than 75% of these costs arose in individuals with two or more ACEs."

Although most audiences won't be up to read the scientific report itself, the findings are rather important for everyone to know.  If you are targeting community businesses - they will certainly understand the impact of medical costs on our society and gross national product.

The study goes into depth of the medical and lifelong (and shortening) effects, but the research included the costs in terms of medical costs and I thought this section of the article would also be helpful.  

Added value of this study
With meta-analyses and population-attributable fraction methods, we pooled data on ACE-attributable risks for leading risk factors for and causes of ill health, and we converted these into annual ACE-attributable disability-adjusted life-years (DALYs) for Europe and north America. We calculated the absolute measures of ill health that could potentially be avoidable by preventing ACEs in childhoods across each global region. Finally, through a human capital approach, we expressed ACE-attributable ill health (in DALYs) as annual financial costs. We estimated that the annual costs from the effect of ACEs on the health outcomes measured were US$581 billion in Europe (equivalent to 2Β·67% of gross domestic product) and $748 billion in north America (equivalent to 3Β·55% of gross domestic product).
Excerpted from 
Hope this helps - 
-- Susan

Add Reply

Copyright Β© 2020, ACEsConnection. All rights reserved.
Link copied to your clipboard.